AbbVie has won expanded European approval of its blockbuster autoimmune drug Rinvoq for the treatment of adults with giant cell arteritis.

Genmab denies the accusation that it knowingly stole confidential information in a $1.8 billion deal to acquire a cancer drug rival.

AbbVie (NYSE: ABBV) today announced that the European Commission (EC) granted marketing authorization to RINVOQ� (upadacitinib; 15 mg, once daily) for the treatment of giant cell arteritis (GCA) in ...

CHICAGO, IL / ACCESS Newswire / March 11, 2025 / Recently, the Northern District of Illinois denied AbbVie's motion to dismiss a lawsuit alleging that AbbVie violated the Illinois Genetic ...

AbbVie (NYSE:ABBV) announced Thursday that ... Citing topline data from its 428-patient SELECT-GCA study, the North Chicago, Illinois-based drugmaker said upadacitinib as a combination therapy ...

into AbbVie's global infrastructure for developing and commercializing therapies for patients in need NORTH CHICAGO, Ill. and HØRSHOLM, Denmark, March 3, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) and ...